Review



anti cd131  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech anti cd131
    Anti Cd131, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd131/product/Proteintech
    Average 93 stars, based on 2 article reviews
    anti cd131 - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    93
    Sino Biological human cd131 heterodimer protein
    Human Cd131 Heterodimer Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd131 heterodimer protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    human cd131 heterodimer protein - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec anti mouse cd131
    Anti Mouse Cd131, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse cd131/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    anti mouse cd131 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Shanghai Model Organisms Center cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background
    Cd131 Deficient Mice ( Csf2rb +/− ) On A C57bl/6j Background, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background/product/Shanghai Model Organisms Center
    Average 90 stars, based on 1 article reviews
    cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    Proteintech anti cd131
    Anti Cd131, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd131/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti cd131 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    Proteintech cd131
    Cd131, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd131/product/Proteintech
    Average 93 stars, based on 1 article reviews
    cd131 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Becton Dickinson anti-cd131 joro 50
    Anti Cd131 Joro 50, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd131 joro 50/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    anti-cd131 joro 50 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    86
    Danaher Inc protein purification soluble cd131
    Protein Purification Soluble Cd131, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protein purification soluble cd131/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    protein purification soluble cd131 - by Bioz Stars, 2026-03
    86/100 stars
      Buy from Supplier

    90
    Becton Dickinson bv421 anti-human cd131
    Divergent IL3Rα and βc expression preferentially occurs at the apex of the hematopoietic cell hierarchy and is linked to poor patient survival in AML. A, IL3Rα and βc gene expression ratio in 451 de novo normal karyotype patients with AML, as shown in reads per kilobase per million mapped reads (RPKM; Beat AML; ref. ). Av, average. B, Kaplan–Meier overall survival curve for normal karyotype patients with AML comparing those with higher or lower than 1.1 ratio of IL3Rα/βc expression in The Cancer Genome Atlas cohort ( n = 184; ref. ). C, Single-cell gene expression of IL3Rα and βc across 11,641 single AML cells from 12 patients , with cell types annotated from . Mean gene expression is depicted for each AML cell type. D, Hierarchical clustering of primary AML patient samples with high ( n = 5) and low ( n = 5) IL3Rα/βc ratio [RNA sequencing (RNA-seq)] combining transcriptional (*; RNA-seq) and immunophenotypic (flow cytometry) profiling in the Toronto cohort. E, IL3Rα and βc gene expression in sorted and functionally validated immunophenotypic cellular fractions from CB . CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors; Gr, granulocytes; HSC, hematopoietic stem cells; MEP, megakaryocyte-erythroid progenitors; MLP, multilymphoid progenitors; Mono, monocytes; MPP, multipotent progenitors. F, Flow cytometric analysis for %IL3Rα hi βc lo population of high ( n = 5, blue) and low ( n = 5, red) IL3Rα/βc transcript ratio AML patient samples (CD3 − CD19 − CD45 + ) in the Toronto cohort based on cell-surface IL3Rα and βc protein expression profiles. CB mononuclear cells ( n = 3) and mobilized peripheral blood (mPB) mononuclear cells ( n = 1) served as controls (ctrl). ns, not significant. G, Correlation of relative abundance of cells with quiescent and primed combined transcriptional phenotypes with %IL3Rα hi /βc lo population in CD3 − CD19 − CD45 + cells with high and low IL3Rα/βc ratio (by RNA-seq) in the Toronto cohort by Pearson analysis. H, Spearman correlation between gene expression and LSC frequency from 88 AML fractions in which specific LSC frequencies were calculated by limiting dilution analysis (LDA) in xenograft assays . IL3Rα ( IL3RA ) and βc ( CSF2RB ) are highlighted. I, IL3Rα/βc transcript ratio from 138 LSC + (engrafting) and 82 LSC − (nonengrafting) fractions . J, Sorting gates for xenotransplanted high/medium (med)/low IL3Rα/βc ratio (CD123 vs. <t>CD131)</t> fractions for patient sample AML#140005 and AML#130578 are shown pregated for viable (SytoxBlue − ) and CD45 + CD3 − CD19 − cells and in relation to an in parallel stained G-CSF mobilized peripheral blood control sample (mPB ctrl) from a healthy donor. K, LSC frequencies of high/med/low IL3Rα/βc ratio fractions from AML#140005 and AML#130578 xenotransplanted in limiting dilution into NSG-SGM3 and NSG mice as estimated from CD45 + CD33 + engraftment (>0.1%) at 7 to 8 weeks after transplantation (see also Supplementary Fig. SIQ). Due to low cell numbers retrieved, the low-ratio fraction of AML#130578 was transplanted only into NSG-SGM3. Open triangle and dotted error bar line indicate an estimated 1/LSC frequency and upper limit of 1. Upper and lower estimated limit (error bars) and P values as calculated by ELDA.
    Bv421 Anti Human Cd131, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bv421 anti-human cd131/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    bv421 anti-human cd131 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Divergent IL3Rα and βc expression preferentially occurs at the apex of the hematopoietic cell hierarchy and is linked to poor patient survival in AML. A, IL3Rα and βc gene expression ratio in 451 de novo normal karyotype patients with AML, as shown in reads per kilobase per million mapped reads (RPKM; Beat AML; ref. ). Av, average. B, Kaplan–Meier overall survival curve for normal karyotype patients with AML comparing those with higher or lower than 1.1 ratio of IL3Rα/βc expression in The Cancer Genome Atlas cohort ( n = 184; ref. ). C, Single-cell gene expression of IL3Rα and βc across 11,641 single AML cells from 12 patients , with cell types annotated from . Mean gene expression is depicted for each AML cell type. D, Hierarchical clustering of primary AML patient samples with high ( n = 5) and low ( n = 5) IL3Rα/βc ratio [RNA sequencing (RNA-seq)] combining transcriptional (*; RNA-seq) and immunophenotypic (flow cytometry) profiling in the Toronto cohort. E, IL3Rα and βc gene expression in sorted and functionally validated immunophenotypic cellular fractions from CB . CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors; Gr, granulocytes; HSC, hematopoietic stem cells; MEP, megakaryocyte-erythroid progenitors; MLP, multilymphoid progenitors; Mono, monocytes; MPP, multipotent progenitors. F, Flow cytometric analysis for %IL3Rα hi βc lo population of high ( n = 5, blue) and low ( n = 5, red) IL3Rα/βc transcript ratio AML patient samples (CD3 − CD19 − CD45 + ) in the Toronto cohort based on cell-surface IL3Rα and βc protein expression profiles. CB mononuclear cells ( n = 3) and mobilized peripheral blood (mPB) mononuclear cells ( n = 1) served as controls (ctrl). ns, not significant. G, Correlation of relative abundance of cells with quiescent and primed combined transcriptional phenotypes with %IL3Rα hi /βc lo population in CD3 − CD19 − CD45 + cells with high and low IL3Rα/βc ratio (by RNA-seq) in the Toronto cohort by Pearson analysis. H, Spearman correlation between gene expression and LSC frequency from 88 AML fractions in which specific LSC frequencies were calculated by limiting dilution analysis (LDA) in xenograft assays . IL3Rα ( IL3RA ) and βc ( CSF2RB ) are highlighted. I, IL3Rα/βc transcript ratio from 138 LSC + (engrafting) and 82 LSC − (nonengrafting) fractions . J, Sorting gates for xenotransplanted high/medium (med)/low IL3Rα/βc ratio (CD123 vs. CD131) fractions for patient sample AML#140005 and AML#130578 are shown pregated for viable (SytoxBlue − ) and CD45 + CD3 − CD19 − cells and in relation to an in parallel stained G-CSF mobilized peripheral blood control sample (mPB ctrl) from a healthy donor. K, LSC frequencies of high/med/low IL3Rα/βc ratio fractions from AML#140005 and AML#130578 xenotransplanted in limiting dilution into NSG-SGM3 and NSG mice as estimated from CD45 + CD33 + engraftment (>0.1%) at 7 to 8 weeks after transplantation (see also Supplementary Fig. SIQ). Due to low cell numbers retrieved, the low-ratio fraction of AML#130578 was transplanted only into NSG-SGM3. Open triangle and dotted error bar line indicate an estimated 1/LSC frequency and upper limit of 1. Upper and lower estimated limit (error bars) and P values as calculated by ELDA.

    Journal: Cancer Discovery

    Article Title: Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia

    doi: 10.1158/2159-8290.CD-22-1396

    Figure Lengend Snippet: Divergent IL3Rα and βc expression preferentially occurs at the apex of the hematopoietic cell hierarchy and is linked to poor patient survival in AML. A, IL3Rα and βc gene expression ratio in 451 de novo normal karyotype patients with AML, as shown in reads per kilobase per million mapped reads (RPKM; Beat AML; ref. ). Av, average. B, Kaplan–Meier overall survival curve for normal karyotype patients with AML comparing those with higher or lower than 1.1 ratio of IL3Rα/βc expression in The Cancer Genome Atlas cohort ( n = 184; ref. ). C, Single-cell gene expression of IL3Rα and βc across 11,641 single AML cells from 12 patients , with cell types annotated from . Mean gene expression is depicted for each AML cell type. D, Hierarchical clustering of primary AML patient samples with high ( n = 5) and low ( n = 5) IL3Rα/βc ratio [RNA sequencing (RNA-seq)] combining transcriptional (*; RNA-seq) and immunophenotypic (flow cytometry) profiling in the Toronto cohort. E, IL3Rα and βc gene expression in sorted and functionally validated immunophenotypic cellular fractions from CB . CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors; Gr, granulocytes; HSC, hematopoietic stem cells; MEP, megakaryocyte-erythroid progenitors; MLP, multilymphoid progenitors; Mono, monocytes; MPP, multipotent progenitors. F, Flow cytometric analysis for %IL3Rα hi βc lo population of high ( n = 5, blue) and low ( n = 5, red) IL3Rα/βc transcript ratio AML patient samples (CD3 − CD19 − CD45 + ) in the Toronto cohort based on cell-surface IL3Rα and βc protein expression profiles. CB mononuclear cells ( n = 3) and mobilized peripheral blood (mPB) mononuclear cells ( n = 1) served as controls (ctrl). ns, not significant. G, Correlation of relative abundance of cells with quiescent and primed combined transcriptional phenotypes with %IL3Rα hi /βc lo population in CD3 − CD19 − CD45 + cells with high and low IL3Rα/βc ratio (by RNA-seq) in the Toronto cohort by Pearson analysis. H, Spearman correlation between gene expression and LSC frequency from 88 AML fractions in which specific LSC frequencies were calculated by limiting dilution analysis (LDA) in xenograft assays . IL3Rα ( IL3RA ) and βc ( CSF2RB ) are highlighted. I, IL3Rα/βc transcript ratio from 138 LSC + (engrafting) and 82 LSC − (nonengrafting) fractions . J, Sorting gates for xenotransplanted high/medium (med)/low IL3Rα/βc ratio (CD123 vs. CD131) fractions for patient sample AML#140005 and AML#130578 are shown pregated for viable (SytoxBlue − ) and CD45 + CD3 − CD19 − cells and in relation to an in parallel stained G-CSF mobilized peripheral blood control sample (mPB ctrl) from a healthy donor. K, LSC frequencies of high/med/low IL3Rα/βc ratio fractions from AML#140005 and AML#130578 xenotransplanted in limiting dilution into NSG-SGM3 and NSG mice as estimated from CD45 + CD33 + engraftment (>0.1%) at 7 to 8 weeks after transplantation (see also Supplementary Fig. SIQ). Due to low cell numbers retrieved, the low-ratio fraction of AML#130578 was transplanted only into NSG-SGM3. Open triangle and dotted error bar line indicate an estimated 1/LSC frequency and upper limit of 1. Upper and lower estimated limit (error bars) and P values as calculated by ELDA.

    Article Snippet: Subsequently, the transduced cells were sorted for viability using Fixable Viability Stain 780 (BD #565388, RRID: AB_2869673) and for IL3Rα and βc coexpression using PE anti-human CD123 (BD #555644, RRID: AB_396001) and BV421 anti-human CD131 (BD #564192, RRID: AB_2738659) antibodies on a MoFlo Astrios (Beckman Coulter), followed by overnight incubation in SCF at 37°C.

    Techniques: Expressing, RNA Sequencing Assay, Flow Cytometry, Staining, Transplantation Assay